Figure 1.
![Fistula closure rates [a] and fistula improvement rates [b] with adalimumab treatment from Week 12 to Week 292 in IMAgINE 1 and IMAgINE 2 in patients with fistulae at baseline (non-responder imputation [NRI] in IMAgINE1, hybrid non-responder imputation [hNRI] in IMAgINE2 and as-observed analyses).](https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/ecco-jcc/12/10/10.1093_ecco-jcc_jjy087/1/jjy08701.jpeg?Expires=1749503557&Signature=fExSxJpkOv8D-16aJ9fQzJ51~qak9b7w9vUNfOQJbkKd74beGO5lzmZ2wlmJky3SOsf~2uJl4VjunHP4GSXTh5IrNdog6CeUbPtNdcRm93KAZvKoPKdxHhqJMt-ni-tU55R5nYVcpv6dcwCgS4z18Fnb0e1oN7U8PHLaNDV2wICXofAH29bmxD9BHutwwTvJ0cNsce1BV6l8JlJ6ZBCOn3Tpq7EWazuNVWzi2mCD5zOyVoV~Gf5ZiVk45xuVmmlxhkdJ9t5--LMfaJVNpb2hLfpeuKVSi0oDrFqvntd5pONPsvnWsO7XO5JNp-Ay~uTRYV68Xki3aWxYpiuzVJxDbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Fistula closure rates [a] and fistula improvement rates [b] with adalimumab treatment from Week 12 to Week 292 in IMAgINE 1 and IMAgINE 2 in patients with fistulae at baseline (non-responder imputation [NRI] in IMAgINE1, hybrid non-responder imputation [hNRI] in IMAgINE2 and as-observed analyses).
